Berkeley Lights, Inc. (BLI)
After hours:
| Previous Close | 20.99 |
| Open | 20.80 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 800 |
| Day's Range | 19.28 - 21.23 |
| 52 Week Range | 17.82 - 113.53 |
| Volume | |
| Avg. Volume | 1,696,274 |
| Market Cap | 1.368B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | May 11, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 73.00 |
- Business Wire
BLI ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Berkeley Lights, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case
SAN DIEGO, December 09, 2021--The suit alleges defendants issued false statements re: Berkley Lights business and prospects, resulting in its stock trading at inflated prices.
- GlobeNewswire
BERKELEY LIGHTS ALERT: Bragar Eagel & Squire, P.C. is Investigating Berkeley Lights on Behalf of Berkeley Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Berkeley Lights, Inc. (“Berkeley Lights” or the “Company”) (NASDAQ: BLI) on behalf of Berkeley Lights stockholders. Our investigation concerns whether Berkeley Lights has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. In July 2020, Berkeley Lights
- GlobeNewswire
Berkeley Lights Debuts in France as MImAbs Acquires the Beacon® Optofluidic System for Antibody Discovery
EMERYVILLE, Calif. and MARSEILLE, France, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, and MImAbs SAS, an emerging CRO that discovers and develops antibodies for immunotechnology therapeutics and research, today announced the acquisition of the Berkeley Lights Beacon® system via a TechAccess subscription to help further its mission of helping its customers in the generation and validation of novel therapeutic antibodies against cancer a
